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ABSTRACT 
 
Cystic fibrosis (CF) is the most common life-shortening autosomal recessive disease in 
Caucasians. The major cause of morbidity and mortality is lung disease, characterized by 
a vicious circle of infection and inflammation. Management of CF requires a 
multifaceted approach, where intensive chest physiotherapy is combined with aggressive 
antibiotic treatment, and tight nutritional follow-up. Vitamin D insufficiency has high 
prevalence among CF patients worldwide. Vitamin D is crucial for maintaining healthy 
skeleton. Recently, extraskeletal functions of vitamin D have been described. These 
include immunomodulatory and glucose-lowering properties. Due to lack of relevant 
studies, vitamin D supplementation in CF is recommended only as one of the means of 
maintaining bone health. The aim of this thesis was to increase our current 
understanding of the impact of vitamin D supplementation in CF patients, and provide 
data needed for designing an efficient vitamin D supplementation policy.  
     First of all, we showed that a majority of Scandinavian CF patients had a suboptimal 
serum 25-hydroxyvitamin D (s25OHD) level (Paper I), and that the vitamin D doses 
needed to increase it were high. Cholecalciferol was more efficient at increasing 
s25OHD than ergocalciferol, and s25OHD monitoring was needed (Paper III).  
     Secondly, we propose that vitamin D induces a broad spectrum of immuno-
modulatory actions in CF. In the well-defined Scandinavian CF population (n=898), 
s25OHD was associated negatively with serum total IgG, and positively with lung 
function (FEV1) in a robust multiple linear regression (MLR) model (Paper I). In line 
with that, three months long ergocalciferol supplementation in Stockholm CF patients 
decreased serum total IgG and IgM, whereas cholecalciferol decreased expression of the 
costimulatory molecule CD40 on dendritic cells. Patients receiving any form of vitamin 
D decreased T cell activation and IL-8 levels at the end of the supplementation. On the 
other hand, certain mechanisms of innate immunity were enhanced, such as MCP-1 and 
sTREM-1. Soluble CD14 increased only in patients reaching 92 < s25OHD < 97 
nmol/L, which suggests bell-shaped relationship between s25OHD and soluble CD14. 
Notably, increase in s25OHD levels was associated with positive changes in lung 
function and in respiratory quality of life scores (Paper III). 
     Moreover, we demonstrated that s25OHD < 30 nmol/L, s25OHD < 50 nmol/L, and 
vitamin D insufficiency degree are independent determinants of HbA1c values in 
Scandinavian CF patients in a MLR model. This indicates that vitamin D may have 
glucose-lowering properties in CF. In addition, s25OHD < 30 nmol/L and vitamin D 
insufficiency degree determined the risk of CF-related diabetes (Paper II). 
     In Paper IV we aimed to assess the ability of CF bronchial epithelial (CFBE) cells to 
convert the inactive 25OHD to the active 1,25(OH)2D, which is an important mechanism 
ensuring adequate local concentrations of the biologically active 1,25(OH)2D in vivo. 
Upon addition of 25OHD (100 nmol/L), the amplitude of the increase in 1,25(OH)2D 
was smaller for the CFBE cells than the non-CF human bronchial epithelial cells (12.0 
versus 33.2 pmol/L). These results indicate that cells harbouring mutations in cftr may 
have impaired ability to activate vitamin D. 
     In conclusion, this thesis contributes to the understanding of the multifunctional 
importance of vitamin D in CF. It creates hypotheses about role of vitamin D in chronic 
inflammation, diabetes and lung function, which need to be studied further. 
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